Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Myasthenia Gravis, a Rare Autoimmune Disorder

Core Insights - Thermo Fisher Scientific has launched the CorEvitas Myasthenia Gravis (MG) Registry to collect real-world data on MG patients in the U.S. to evaluate therapies and improve patient care [1][4] Company Overview - Thermo Fisher Scientific is a leading company in the scientific services sector, with annual revenues exceeding $40 billion [6][12] - The company employs around 100,000 people and operates under various well-known brands [7][14] Registry Details - The CorEvitas MG Registry aims to gather clinical data from patients diagnosed with both ocular and generalized forms of MG, tracking disease progression and treatment effectiveness [4][5] - The registry is now active in the U.S., with the first patient enrolled on November 10 [3] Disease Context - Myasthenia Gravis is a rare autoimmune disorder affecting muscle strength, with over 70,000 diagnosed cases in the U.S. [2] - Symptoms can range from mild to severe, including periods of remission and severe episodes requiring medical intervention [2] Research and Development - The registry will support long-term data collection for regulatory-grade research, enhancing understanding of MG and its treatment [4][5] - The initiative is guided by experts from the University of North Carolina and the University of Miami [4]